141 results on '"Gunaratnam C"'
Search Results
2. A specialized method of sputum collection and processing for therapeutic interventions in cystic fibrosis
3. Risk factors for totally implantable venous access device-associated complications in cystic fibrosis
4. WS03.05 Multicenter validation of the cystic fibrosis-ABLE score as a predictor of outcome and therapeutic response in cystic fibrosis
5. WS18.02 ETI triple therapy shows sustained, progressive normalisation of airway cytokine and antiprotease balance and systemic inflammation over one year of treatment
6. ETI Triple Therapy Shows Sustained, Progressive Normalisation of Airway Cytokine and Antiprotease Balance and Systemic Inflammation Over One Year of Treatment
7. Circadian Protein Localisation in Monocytes of Severe Alpha 1 Antitrypsin Deficiency
8. Multicenter Validation of the CF-ABLE Score as a Predictor of Outcome and Therapeutic Response in Cystic Fibrosis
9. Diurnal Description of Alpha 1 Antitrypsin Levels and Other Inflammatory Markers in Healthy Humans and Alpha 1 Antitrypsin Deficiency Patients
10. Is Genetic Discrimination a Problem in AATD? An Irish Perspective
11. Safety and Efficacy of COVID-19 Vaccination in Severe Alpha-1 Antitrypsin Deficiency
12. Family Screening in Severe Alpha-1 Antitrypsin Deficiency - Too Little, Too Late? An Argument for Newborn Screening
13. PiSS Alpha-1 Antitrypsin Deficiency: A Clinical Risk Variant?
14. 156 Multicenter validation of the CF-ABLE score as a predictor of outcome and therapeutic response in cystic fibrosis
15. Pulmonary alveolar proteinosis
16. Bronchoalveolar Lavage Cell Differential in Alpha-1 Antitrypsin Deficiency
17. The Impact of Elexacaftor/Tezacaftor/Ivacaftor on the Protease-Antiprotease Balance in Cystic Fibrosis Airways
18. The Societal Cost of ZZ Alpha-1 Antitrypsin Deficiency in an Irish Population
19. Longitudinal Rates of Decline in Spirometry in AAT Deficiency (AATD) - A Collaboration Between Ireland, Switzerland and Austria
20. The Use of Transient Elastography for Assessing for Alpha-1 Antitrypsin-Related Liver Disease and Its Discordance with Liver Ultrasonography
21. An Update from the Irish National Alpha-1 Antitrypsin Deficiency Targeted Detection Programme
22. The Effect of Cocooning on Patient-Reported Pulmonary Exacerbation Frequency in A ZZ Alpha-1 Antitrypsin Deficient Irish Population
23. 550: Effect of elexacaftor/tezacaftor/ivacaftor on LPS- and ATP-induced inflammasome activation in monocytes of patients with cystic fibrosis
24. 559: Impact of elexacaftor/tezacaftor/ivacaftor on airway levels of ATP and IL-1b, markers of cystic fibrosis inflammation
25. WS05.3 P2X7 receptor inhibition limits inflammatory response of monocytes to LPS and ATP through inflammasome regulation in cystic fibrosis
26. P071 Real-world pregnancy data and outcomes in an era post-CFTR modulation therapies: an Irish centre's perspective
27. Cystic fibrosis, common variable immunodeficiency and Aspergers syndrome: an immunological and behavioural challenge
28. EVALUATION OF SERUM DERIVED BIOACTIVE BIOMARKER OF INFLAMMATION IN CYSTIC FIBROSIS: 82★
29. Real-World Evaluation of the CF-Able Score as a Clinical Prognostic Tool in Cystic Fibrosis
30. Attitudes of Irish Second-Level Students Towards Vaping
31. Thrombolysis for indwelling catheter related thrombosis and superior vena cava obstruction in cystic fibrosis: a case series
32. SLEEPING IN EACH MORNING: IS IT AFFECTING MY CYSTIC FIBROSIS?: 671⋆
33. MALE INFERTILITY IN CYSTIC FIBROSIS (CF): AN IRISH PERSPECTIVE: 670⋆
34. Attenuation of Bronchial Hyperresponsiveness to Histamine by Vitamin C in asthmatic subjects.
35. Modulation of the T cell response to antigenic stimulation in atopic asthmatics by the balance of macrophage subsets.
36. Metabolic Reprogramming of the Cystic Fibrosis Neutrophil Drives Interleukin-1β via the NLRP3 Inflammasome
37. Repeatability of transient elastography in children.
38. Severe Thrombophlebitis With Naftidrofuryl Oxalate
39. Pulmonary alveolar proteinosis
40. Risk factors for totally implantable venous access device-associated complications in cystic fibrosis
41. 59 Ralstonia mannitolilytica – an emerging threat in cystic fibrosis and lung transplantation
42. Isolated Unilateral Pulmonary Artery Agenesis complicated by Symptomatic Aspergilloma.
43. WS7.4 Inhaled aztreonam lysine (Cayston) therapy significantly improves lung function, weight, hospitalisations and excerbation rates prospectively – an Irish and UK real world experience
44. WS7.6 UK and Ireland review of ivacaftor in severe CF: Impact on lung function and weight
45. 54 UK and Ireland review of ivacaftor in severe CF: Impact on hospitalisations and antibiotic use
46. WS17.7 Itraconazole up-regulates the vitamin D receptor and reduces T-helper 2 responses in individuals with cystic fibrosis colonized with Aspergillus fumigatus
47. 290 Comparison of totally implantable venous access device complications in a cystic fibrosis cohort and a haemodialysis cohort
48. WS3.6 The CF-ABLE score: a novel clinical prediction tool in cystic fibrosis
49. WS23.3 Sputum Candida albicans is associated with radiological abnormalities in a cystic fibrosis cohort
50. Cystic fibrosis, common variable immunodeficiency and Aspergers syndrome: an immunological and behavioural challenge
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.